Literature DB >> 7093112

The short term effects of propranolol, atenolol and labetalol on antipyrine kinetics in normal subjects.

T K Daneshmend, C J Roberts.   

Abstract

1 The effects of three day courses of propranolol 40 mg three times daily, atenolol 100 mg twice daily and labetalol 100 mg three times daily on antipyrine kinetics were examined in 13 normal subjects. 2 The mean antipyrine clearance initially was 41.3 +/- 12.4 ml/min (mean +/- s.d.) and fell to 35.0 +/- 12.1 ml/min following propranolol (P less than 0.025), 34.5 +/- 9.5 ml/min following atenolol (P less than 0.01), and 35.2 +/- 8.6 ml/min following labetalol (P less than 0.05). 3 The prolongation in antipyrine half-life was significant only following atenolol. Propranolol only caused a significant reduction in the volume of distribution of antipyrine. 4 These adrenoceptor antagonists appear to decrease antipyrine clearance in normal subjects. The reduction in antipyrine clearance was similar with all three drugs and appeared to be independent of the differing lipid solubilities and pharmacological profiles of the adrenoceptor antagonists examined.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7093112      PMCID: PMC1402031          DOI: 10.1111/j.1365-2125.1982.tb01872.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  The antipyrine test in clinical pharmacology: conceptions and misconceptions.

Authors:  E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

2.  High-density lipoprotein cholesterol and antihypertensive drugs: the Oslo study.

Authors:  A Helgeland; I Hjermann; P Leren; S Enger; I Holme
Journal:  Br Med J       Date:  1978-08-05

3.  Beta-blockers and plasma triglycerides.

Authors:  J Shaw; J D England; A S Hua
Journal:  Br Med J       Date:  1978-04-15

4.  Comparison of plasma levels of antipyrine, tolbutamide, and warfarin after oral and intravenous administration.

Authors:  P B Andreasen; E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1974-12       Impact factor: 6.875

5.  Effect of different beta-adrenergic receptor blocking agents on hexobarbital induced narcosis in mice.

Authors:  K Hermansen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1969

6.  Reduction in lidocaine clearance during continuous infusion and by coadministration of propranolol.

Authors:  H R Ochs; G Carstens; D J Greenblatt
Journal:  N Engl J Med       Date:  1980-08-14       Impact factor: 91.245

7.  Physiological and pharmacological variability in estimated hepatic blood flow in man.

Authors:  T K Daneshmend; L Jackson; C J Roberts
Journal:  Br J Clin Pharmacol       Date:  1981-05       Impact factor: 4.335

8.  Antipyrine metabolism during the menstrual cycle.

Authors:  E F Riester; E J Pantuck; C B Pantuck; G T Passananti; E S Vesell; A H Conney
Journal:  Clin Pharmacol Ther       Date:  1980-09       Impact factor: 6.875

9.  Metabolic consequences of atenolol and propranolol in treatment of essential hypertension.

Authors:  J L Day; N Simpson; J Metcalfe; R L Page
Journal:  Br Med J       Date:  1979-01-13

10.  Impairment of antipyrine clearance in humans by propranolol.

Authors:  D J Greenblatt; K Franke; D H Huffman
Journal:  Circulation       Date:  1978-06       Impact factor: 29.690

View more
  14 in total

1.  Single dose pharmacokinetics and pharmacodynamics of oral oxazepam during concomitant administration of propranolol and labetalol.

Authors:  J Sonne; M Døssing; S Loft; K L Olesen; A Vollmer-Larsen; M A Victor; O Hamberg; H Thyssen
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

Review 2.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

3.  Differential effect of continuous administration of beta-adrenoceptor antagonists on antipyrine and phenytoin clearance.

Authors:  H Perrild; L Kayser; H E Poulsen; L Skovsted; B Jørgensen; J M Hansen
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

4.  The effect of verapamil on antipyrine pharmacokinetics and metabolism in man.

Authors:  D Bach; R Blevins; N Kerner; M Rubenfire; D J Edwards
Journal:  Br J Clin Pharmacol       Date:  1986-06       Impact factor: 4.335

5.  Pharmacokinetic and pharmacodynamic interaction study of diazepam and metoprolol.

Authors:  U Klotz; I W Reimann
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

6.  Lack of effect of atenolol on antipyrine clearance.

Authors:  G T Tucker; N D Bax; M S Lennard; K Crewe; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

Review 7.  Clinical pharmacokinetics of labetalol.

Authors:  J J McNeil; W J Louis
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

Review 8.  Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.

Authors:  K L Goa; P Benfield; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

9.  Lack of effect of atenolol on the pharmacokinetics of theophylline.

Authors:  L A Cerasa; J S Bertino; E A Ludwig; M Savliwala; E Middleton; R L Slaughter
Journal:  Br J Clin Pharmacol       Date:  1988-12       Impact factor: 4.335

10.  Study of the influence of nifedipine on the pharmacokinetics and pharmacodynamics of propranolol, metoprolol and atenolol.

Authors:  D Gangji; M Juvent; G Niset; M Wathieu; M Degreve; R Bellens; J Poortmans; S Degre; T J Fitzsimons; A Herchuelz
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.